Resistance to molecularly targeted therapies is often due to mutations in the drug target, but there is growing recognition of other modes of tumor esc...

Scientists have found a protein that empowers prostate tumors to resist hormone therapy.

Thousands of oncology experts from around the world will tune in April 27 and 28 for the American Association for Cancer Research’s (AACR) virtual annual meeting I. The meeting is the first of two virtual sessions, with clinical trial plenary sessions, clinical trial poster sessions, several minisymposia, and more. The AACR virtual annual meeting II will be held June 22 through 24.

Androgen-deprivation therapy, a mainstay of prostate cancer treatment, may give prostate cells new growth abilities, scientists at Memorial Sloan Kettering have found.

Scientists at Memorial Sloan Kettering have created a model of rectal cancer using human-tumor-derived organoids.

Mutations in a gene called FOXA1 are responsible for a distinct class of prostate cancer tumors, MSK researchers have found.

Doctors are developing treatment strategies that target the androgen receptor, which is found in many triple-negative breast cancers.

Eight leading cancer centers are coming together to share genomic sequencing data, in the hope of making faster progress in curing cancer.

The 2016 annual meeting of the American Association for Cancer Research (AACR) ended with a visit from the Vice President.